Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.

ABSTRACT:

Purpose

The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti-programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.

Materials and methods

Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, s

SUBMITTER: Lim SM 

PROVIDER: S-EPMC7577826 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature